Author: Transgene S.A.

Posted Date:

April 9, 2026

Availability of Transgene’s 2025 Universal Registration Document (URD)

Transgene S.A.

April 9, 2026
Transgene to Participate in Upcoming Investor Meetings

Transgene S.A.

April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene S.A.

April 2, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

Transgene S.A.

March 26, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Transgene S.A.

March 24, 2026
Transgene Announces Financial Calendar for 2026

Transgene S.A.

February 7, 2026
Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer

Transgene S.A.

February 2, 2026
Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer

Transgene S.A.

February 2, 2026